

# Accepted Manuscript

Title: Towards quantitative cut-offs for insomnia: how current diagnostic criteria mischaracterize remission.

Author: Vivek Pillai, Thomas Roth, Christopher L. Drake

PII: S1389-9457(16)00049-6  
DOI: <http://dx.doi.org/doi: 10.1016/j.sleep.2016.01.013>  
Reference: SLEEP 3006

To appear in: *Sleep Medicine*

Received date: 28-9-2015  
Revised date: 14-1-2016  
Accepted date: 16-1-2016

Please cite this article as: Vivek Pillai, Thomas Roth, Christopher L. Drake, Towards quantitative cut-offs for insomnia: how current diagnostic criteria mischaracterize remission., *Sleep Medicine* (2016), <http://dx.doi.org/doi: 10.1016/j.sleep.2016.01.013>.

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.



**Towards quantitative cut-offs for insomnia: How current diagnostic criteria mischaracterize remission.**

Vivek Pillai, PhD; Thomas Roth, PhD; Christopher L. Drake, PhD

Sleep Disorders and Research Center, Henry Ford Hospital, Detroit, MI

This study was supported by an NIMH Grant (R01 MH082785) and an investigator initiated research award from Merck & Co, both to Dr. Drake. The NIMH and Merck had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; and preparation, review, or approval of the manuscript.

Conflicts of Interest Disclosures: Dr. Roth has served as consultant for Abbott, Accadia, AstraZenca, Aventis, AVER, Bayer, BMS, Cypress, Ferrer, Glaxo Smith Kline, Impax, Intec, Jazz, Johnson and Johnson, Merck, Neurocrine, Novartis, Proctor and Gamble, Pfizer, Purdue, Shire, Somaxon, Transcept; has received research support from Cephalon, Merck, and Transcept; and has served on speakers bureau for Purdue. Dr. Drake has received research support from Merck, Interclinic, Aladdin Dreamer, and Teva; and has served on speakers bureau for Teva and Merck. Dr. Pillai indicated no financial conflicts of interest.

Abstract Word Count: 248; Text Word Count: 3012; Tables: 2; Figures: 1

Address correspondence to: Christopher L. Drake, PhD, Sleep Disorders and Research Center, Henry Ford Hospital, Detroit, MI 48202; Tel: (248) 344 6672; E-mail: [cdrake1@hfhs.org](mailto:cdrake1@hfhs.org)

Download English Version:

<https://daneshyari.com/en/article/5643999>

Download Persian Version:

<https://daneshyari.com/article/5643999>

[Daneshyari.com](https://daneshyari.com)